Elanco Animal Health Incorporated Income Tax Expense
Elanco Animal Health Incorporated (ELAN) reported Income Tax Expense of $2.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-05
- Elanco Animal Health Incorporated income tax expense (benefit) for the quarter ending 2026-06-30 was $2.00M, a 85.71% decline year-over-year.
- Elanco Animal Health Incorporated income tax expense (benefit) for the quarter ending 2026-03-31 was $30.00M.
- Elanco Animal Health Incorporated income tax expense (benefit) for the quarter ending 2025-12-31 was $17.00M.
- Elanco Animal Health Incorporated income tax expense (benefit) for the quarter ending 2025-09-30 was -$16.00M, a 108.21% decline year-over-year.
- Elanco Animal Health Incorporated income tax expense (benefit) for fiscal 2025 was $8.00M, a 94.67% decline from fiscal 2024.
- Elanco Animal Health Incorporated income tax expense (benefit) for fiscal 2024 was $150.00M, a 316.67% increase from fiscal 2023.
- Elanco Animal Health Incorporated income tax expense (benefit) for fiscal 2023 was $36.00M, a 500.00% increase from fiscal 2022.
- Elanco Animal Health Incorporated income tax expense (benefit) for fiscal 2022 was $6.00M.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 3 month as first filed | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 6 month as first filed | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 9 month as first filed | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.00M 10-Q · filed 2026-08-05 | $32.00M 10-Q · filed 2026-08-05 | $49.00M derived: sum of 3 quarters · filed 2026-08-05 | $33.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $30.00M 10-Q · filed 2026-05-06 | $47.00M derived: sum of 2 quarters · filed 2026-05-06 | $31.00M derived: sum of 3 quarters · filed 2026-05-06 | $45.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.00M derived: sum of 2 quarters · filed 2026-02-24 | $15.00M derived: sum of 3 quarters · filed 2026-08-05 | $8.00M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | -$16.00M 10-Q · filed 2025-11-05 | -$2.00M derived: sum of 2 quarters · filed 2026-08-05 | -$9.00M 10-Q · filed 2025-11-05 | -$52.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $14.00M 10-Q · filed 2026-08-05 | $7.00M 10-Q · filed 2026-08-05 | -$36.00M derived: sum of 3 quarters · filed 2026-08-05 | $159.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$7.00M 10-Q · filed 2026-05-06 | -$50.00M derived: sum of 2 quarters · filed 2026-05-06 | $145.00M derived: sum of 3 quarters · filed 2026-05-06 | $163.00M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$43.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $152.00M derived: sum of 2 quarters · filed 2026-02-24 | $170.00M derived: sum of 3 quarters · filed 2026-02-24 | $150.00M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $195.00M 10-Q · filed 2025-11-05 | $213.00M derived: sum of 2 quarters · filed 2025-11-05 | $193.00M 10-Q · filed 2025-11-05 | $207.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $18.00M 10-Q · filed 2025-08-07 | -$2.00M 10-Q · filed 2025-08-07 | $12.00M derived: sum of 3 quarters · filed 2026-02-24 | $11.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | -$20.00M 10-Q · filed 2025-05-07 | -$6.00M derived: sum of 2 quarters · filed 2026-02-24 | -$7.00M derived: sum of 3 quarters · filed 2026-02-24 | $11.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $13.00M derived: sum of 2 quarters · filed 2026-02-24 | $31.00M derived: sum of 3 quarters · filed 2026-02-24 | $36.00M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | -$1.00M 10-Q · filed 2024-11-07 | $17.00M derived: sum of 2 quarters · filed 2024-11-07 | $22.00M 10-Q · filed 2024-11-07 | -$13.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $18.00M 10-Q · filed 2024-08-08 | $23.00M 10-Q · filed 2024-08-08 | -$12.00M derived: sum of 3 quarters · filed 2025-02-25 | $9.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $5.00M 10-Q · filed 2024-05-08 | -$30.00M derived: sum of 2 quarters · filed 2025-02-25 | -$9.00M derived: sum of 3 quarters · filed 2025-02-25 | -$13.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | -$35.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$14.00M derived: sum of 2 quarters · filed 2025-02-25 | -$18.00M derived: sum of 3 quarters · filed 2025-02-25 | $6.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $21.00M 10-Q · filed 2023-11-07 | $7.00M 10-Q · filed 2022-11-08 | $17.00M derived: sum of 2 quarters · filed 2023-11-07 | $41.00M 10-Q · filed 2023-11-07 | $34.00M 10-Q · filed 2022-11-08 | $26.00M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | -$4.00M 10-Q · filed 2023-08-07 | $4.00M 10-Q · filed 2022-08-08 | $20.00M 10-Q · filed 2023-08-07 | $27.00M 10-Q · filed 2022-08-08 | $5.00M derived: sum of 3 quarters · filed 2023-08-07 | -$17.00M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | $24.00M 10-Q · filed 2023-05-09 | $23.00M 10-Q · filed 2022-05-09 | $9.00M derived: sum of 2 quarters · filed 2023-05-09 | -$13.00M derived: sum of 3 quarters · filed 2023-05-09 | -$50.00M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | -$15.00M 10-K · filed 2023-03-01 | -$37.00M derived: sum of 2 quarters · filed 2023-03-01 | -$74.00M derived: sum of 3 quarters · filed 2023-03-01 | -$88.00M 10-K · filed 2024-02-26 | -$95.00M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | -$22.00M 10-K · filed 2023-03-01 | -$26.00M 10-Q · filed 2021-11-05 | -$59.00M derived: sum of 2 quarters · filed 2023-03-01 | -$71.00M 10-Q · filed 2022-11-08 | -$67.30M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | -$37.00M 10-K · filed 2023-03-01 | -$26.00M 10-Q · filed 2021-08-09 | -$45.00M 10-Q · filed 2022-08-08 | -$45.30M derived: sum of 3 quarters · filed 2023-03-01 | -$119.30M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | -$13.00M 10-K · filed 2023-03-01 | -$19.00M 10-Q · filed 2021-05-07 | -$8.30M derived: sum of 2 quarters · filed 2023-03-01 | -$82.30M derived: sum of 3 quarters · filed 2023-03-01 | -$106.30M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $4.70M 10-K · filed 2021-03-01 | -$69.30M derived: sum of 2 quarters · filed 2021-11-05 | -$93.30M derived: sum of 3 quarters · filed 2021-11-05 | -$103.00M 10-K · filed 2023-03-01 | -$111.90M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$74.00M 10-Q · filed 2021-11-05 | -$98.00M derived: sum of 2 quarters · filed 2021-11-05 | -$117.00M 10-Q · filed 2021-11-05 | -$116.60M 10-Q · filed 2020-11-06 | -$111.80M derived: sum of 4 quarters · filed 2021-11-05 | |||
| 2020-06-30 | -$24.00M 10-Q · filed 2021-08-09 | -$23.90M 10-Q · filed 2020-07-30 | -$43.00M 10-Q · filed 2021-08-09 | -$42.60M 10-Q · filed 2020-07-30 | -$37.80M derived: sum of 3 quarters · filed 2021-08-09 | -$60.30M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | -$19.00M 10-Q · filed 2021-05-07 | -$18.70M 10-Q · filed 2020-05-07 | -$13.80M derived: sum of 2 quarters · filed 2021-05-07 | -$36.30M derived: sum of 3 quarters · filed 2021-05-07 | -$22.00M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $5.20M 10-K · filed 2021-03-01 | -$17.30M derived: sum of 2 quarters · filed 2021-03-01 | -$3.00M derived: sum of 3 quarters · filed 2021-03-01 | $10.00M 10-K · filed 2022-02-28 | $10.30M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | -$22.50M 10-Q · filed 2020-11-06 | -$8.20M derived: sum of 2 quarters · filed 2020-11-06 | $5.10M 10-Q · filed 2020-11-06 | -$13.50M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $14.30M 10-Q · filed 2020-07-30 | $27.60M 10-Q · filed 2020-07-30 | $9.00M derived: sum of 3 quarters · filed 2020-07-30 | $27.60M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2019-03-31 | $13.30M 10-Q · filed 2020-05-07 | -$5.30M derived: sum of 2 quarters · filed 2020-05-07 | $13.30M derived: sum of 3 quarters · filed 2020-05-07 | $36.10M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$18.60M 10-K · filed 2020-02-28 | $0.00 derived: sum of 2 quarters · filed 2020-02-28 | $22.80M derived: sum of 3 quarters · filed 2020-02-28 | $27.60M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $18.60M 10-K · filed 2020-02-28 | $41.40M derived: sum of 2 quarters · filed 2020-02-28 | $46.20M 10-Q · filed 2019-11-08 | $52.30M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $22.80M 10-K · filed 2020-02-28 | $27.60M 10-Q · filed 2019-08-13 | $33.70M derived: sum of 3 quarters · filed 2020-02-28 | $45.30M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $4.80M 10-K · filed 2020-02-28 | $10.90M derived: sum of 2 quarters · filed 2020-02-28 | $22.50M derived: sum of 3 quarters · filed 2020-02-28 | $37.50M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2017-12-31 | $6.10M 10-K · filed 2019-02-20 | $17.70M derived: sum of 2 quarters · filed 2019-02-20 | $32.70M derived: sum of 3 quarters · filed 2019-02-20 | $78.10M 10-K · filed 2020-02-28 | ||||
| 2017-09-30 | $11.60M 10-K · filed 2019-02-20 | $26.60M derived: sum of 2 quarters · filed 2019-02-20 | $72.00M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $15.00M 10-K · filed 2019-02-20 | $60.40M derived: sum of 2 quarters · filed 2019-02-20 | ||||||
| 2017-03-31 | $45.40M 10-K · filed 2019-02-20 | |||||||
| 2016-12-31 | $25.50M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |